Moving forward in colorectal cancer research, what proteomics has to tell
Nerea Bitarte, Eva Bandrés, Ruth Zárate, Natalia Ramirez, Jesus Garcia-Foncillas
Laboratory of Pharmacogenomics, Center for Medical Applied Research, Unit of Clinical Genetics, University Clinic, Department of Oncology and Radiotherapy, University Clinic, University of Navarra, Pamplona 31008, Spain
Magazine: World Journal of Gastroenterology
Date: Nov 28, 2007Clinical Genetics Unit [SP]
Colorectal cancer is the third most common cancer and is highly fatal.
During the last several years, research has been primarily based on the study of expression profiles using microarray technology. But now, investigators are putting into practice proteomic analyses of cancer tissues and cells to identify new diagnostic or therapeutic biomarkers for this cancer. Because the proteome reflects the state of a cell, tissue or organism more accurately, much is expected from proteomics to yield better tumor markers for disease diagnosis and therapy monitoring.
This review summarizes the most relevant applications of proteomics the biomarker discovery for colorectal cancer.
CITATION World J Gastroenterol. 2007 Nov 28;13(44):5813-21
you maybe interested
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.